News
One of the most striking things about Bungie’s Marathonis its presentation. The sci-fi extraction shooter combines bleak ...
SPIDER-MAN: BRAND NEW DAY Rumored To Introduce "Dark Female Character" With A Japanese-Inspired Look
We have some rumored details on costumes for a couple of characters from Spider-Man: Brand New Day, including a "dark, ...
MERIT, Your Clinical Endpoint Expert We’re proud to offer ORC™ as a novel way of measuring disease progression that may support new and existing treatments for Dry AMD.”— Dr. David Bingama... "Kalkine ...
The poster, titled “Outer Retina-Choroid en ... Ophthalmology of MERIT. About the Presentation: • Title: “Outer Retina-Choroid en face Image, ORC™: Characterization of A Novel Morphologic ...
Gain Therapeutics' lead drug candidate, GT-02287, is in clinical development for the treatment of Parkinson's disease (PD) with or without a GBA1 mutation. The orally administered, brain-penetrant ...
Session A-2 Room 339: Leverage AI in Psychology: Finding a Use Case Presentation 1: Finding a Use Case: Building a Scheduling GPT: Olivia Velez, Psychology Presentation 2: Finding a Use Case: Natural ...
NEUVOGEN Announces Poster Presentation at the American Association of Cancer Research Annual Meeting
SAN DIEGO, April 29, 2025 /PRNewswire/ -- NEUVOGEN, Inc. ("NEUVOGEN THERAPEUTICS" or "NEUVOGEN"), a San Diego based biotechnology company, will present data that its next generation whole tumor ...
Thousand Oaks, Calif.-based Capsida Biotherapeutics (Capsida) has announced its slate of seven scientific presentations, three oral and four in poster form, that have been accepted for the 28th Annual ...
today announced that the Company will give two poster presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting being held May 4-8, 2025, in Salt Lake City, Utah.
Calluna Pharma AS (Calluna), a clinical stage biotechnology company pioneering first-in-class antibodies to treat inflammatory and fibrotic diseases, today announced that the company will present ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results